Tsumura & Co. (TSMRF) Stock Price & Analysis
Tsumura & Co. (TSMRF) closed at USD 23.2 on Friday, October 23, 2026, up 0.00% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 23.2; the Oct 23, 2026 session ranged USD 28.15–28.15 on volume of 100 shares. Market capitalization is $1.73B, with a 52-week range of USD 23.2–28.15 (PNK). Source: Nexqual, retrieved October 24, 2026 at 17:53 UTC.
Also available as compact Markdown for AI agents: nexqual.com/TSMRF.md
Key facts (TSMRF)
- Analysts: None.
- Total return with dividends: 1Y -107.6% vs S&P 500 +13.4%; 5Y -398.4% vs S&P 500 +76.9%.
- Next earnings: 2026-11-09, EPS estimate USD —, revenue estimate $54.4B.
Analysts (TSMRF)
Consensus None.
Total return (dividends reinvested) (TSMRF)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -107.6% | -398.4% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | — | — |
| Volatility (annualized) | — | — |
| Max drawdown | -141.6% (Mar 2026→Mar 2026) | -1001.6% (Mar 2022→Sep 2022) |
TSMRF analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | — | — | — | $54.37B | — |
| Next quarter (ends Dec 2026) | — | — | — | $58.33B | — |
| Current fiscal year (ends Mar 2027) | — | — | — | $214.86B | — |
| Next fiscal year (ends Mar 2028) | — | — | — | $228.12B | — |
Key Statistics (as of October 24, 2026 at 17:53 UTC)
| Price | USD 23.2 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 23.2 |
| Open | USD 28.15 |
| Day Range | USD 28.15 – 28.15 |
| 52-Week Range | USD 23.2 – 28.15 |
| Volume | 100 shares |
| Market Cap | $1.73B |
| Exchange | PNK |
Technical Analysis (TSMRF)
Nexqual's technical model rates TSMRF "BUY" based on 4 bullish and 2 bearish signals across 127 daily candles, as of October 24, 2026 at 17:53 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 23.2) |
| MACD | 0 (negative) |
Analyst Ratings (TSMRF)
Wall Street analysts rate TSMRF "None", per Nexqual as of October 24, 2026 at 17:53 UTC.
| Consensus Rating | None |
|---|
Earnings (TSMRF)
| Next Earnings Date | 2026-11-09 |
|---|---|
| Revenue Estimate | $54.37B |
Source: Nexqual, October 24, 2026 at 17:53 UTC.
Financials & Fundamentals (TSMRF)
| Total Revenue | $199.22B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +15.30% |
| Gross Margin | +46.98% |
| Operating Margin | +15.86% |
| Profit Margin | +15.16% |
| ROE | +9.32% |
| Debt / Equity | 0.39 |
| Current Ratio | 3.55 |
| Total Cash | $77.28B |
| Total Debt | $148.07B |
Source: Nexqual, October 24, 2026 at 17:53 UTC.
Financial Health Score (TSMRF)
Nexqual rates Tsumura & Co.'s overall financial health "Mixed" across five dimensions, as of October 24, 2026 at 17:53 UTC.
| Growth | Mixed — Revenue +0.5% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 47%, operating 16% (last 12 months) |
| Balance Sheet | Strong — JPY 77.3B cash vs JPY 148.1B debt |
| Cash Flow | Solid — Operating cash flow JPY 21.4B (TTM) |
| Efficiency | Mixed — ROE 9%, ROA 4.1% |
Ownership (TSMRF)
| Insider Ownership | +5.54% |
|---|---|
| Institutional Ownership | +51.97% |
| Shares Outstanding | 74.55M |
| Float | 63.56M |
Source: Nexqual, October 24, 2026 at 17:53 UTC.
Leadership (TSMRF)
Tsumura & Co. is led by Terukazu Kato, President, CEO & Chairman, per Nexqual as of October 24, 2026 at 17:53 UTC.
| President, CEO & Chairman | Terukazu Kato |
|---|---|
| CFO & Head of the Corporate Management Division | Kaoru Kobayashi |
| CTO, Head of Research & Development Division and Director | Akihito Konda |
| Executive Officer & Chinese Herbal Medicine Platform Director | Yoshiharu Watanabe |
Major Backers & Investors (TSMRF)
Notable institutional backers of Tsumura & Co. include Goldman Sachs, Victory Portfolios-Victory Trivalent International Small-Cap Fund, Bridge Builder Trust-Bridge Builder International Equity Fund, according to Nexqual as of October 24, 2026 at 17:53 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Goldman Sachs | 1.54% |
| Victory Portfolios-Victory Trivalent International Small-Cap Fund | 0.71% |
| Bridge Builder Trust-Bridge Builder International Equity Fund | 0.59% |
| HARBOR FUNDS-Harbor International Fund | 0.45% |
| DFA INVESTMENT TRUST CO-The Japanese Small Company Series | 0.37% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.1% |
| BlackRock | 0.85% |
| Dimensional Fund Advisors | 0.33% |
Source: Nexqual, October 24, 2026 at 17:53 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUPN | Supernus Pharmaceuticals, Inc. | USD 40.7 | ▼ 3.26% |
| BHC | Bausch Health Companies Inc. | USD 6.44 | ▼ 0.77% |
| HCM | HUTCHMED (China) Limited | USD 14.36 | ▲ 0.56% |
| AMLX | Amylyx Pharmaceuticals, Inc. | USD 27.2 | ▼ 4.8% |
| RGC | Regencell Bioscience Holdings L | USD 7.67 | ▼ 21.81% |
| LQDA | Liquidia Corporation | USD 42.65 | ▲ 7.46% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 17:53 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt